As of Wednesday close, Zomedica Corp.’s (AMEX:ZOM) stock was down -$0.01, moving down -3.84 percent to $0.17. The average number of shares traded per day over the past five days has been 4,454,440 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0076 fall in that time frame. In the last twenty days, the average volume was 3,336,650, while in the previous 50 days, it was 4,062,600.
Since last month, ZOM stock retreated -10.18%. Shares of the company fell to $0.1608 on 09/15/23, the lowest level in the past month. A 52-week high of $0.34 was reached on 01/18/23 after having rallying from a 52-week low of $0.15. Since the beginning of this year, ZOM’s stock price has risen by 4.42% or $0.0072, and marked a new high 6 times. However, the stock has declined by -49.19% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ZOM stock investors should be aware that Zomedica Corp. (ZOM) stock had its last reported insider trading activity 118 days ago on May 26. HEATON LARRY C II, the CEO of the company, purchased of 100,000 shares for $0.19 on May 26. It resulted in a $19,090 investment by the insider. POWERS JOHNNY D added 100,000 shares at an average price of $0.19 on May 25. The insider now owns 1,600,000 shares following the transaction.
Valuation Metrics
The stock’s beta is 0.98. Besides these, the trailing price-to-sales (P/S) ratio of 7.88, the price-to-book (PB) ratio of 0.65.
Financial Health
In the three months ended June 29, Zomedica Corp.’s quick ratio stood at 18.90, while its current ratio was 19.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 70.10% percent. Based on annual data, ZOM earned $13.65 million in gross profit and brought in $18.93 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -7.30%. Return on equity (ROE) for the past 12 months was -7.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ZOM’s revenue rose 15.84% to $5.48 million during the quarter, while net income inched up to $5.05 million. While analysts expected Zomedica Corp. to report $0 quarterly earnings, the actual figure was $0 per share. During the quarter, the company generated -$5.87 million in EBITDA. The liabilities of Zomedica Corp. were 15.3 million at the end of its most recent quarter ended June 29, and its total debt was $1.42 million. The value of shareholders’ equity is $979.95 million.
Technical Picture
This quick technical analysis looks at Zomedica Corp.’s (ZOM) price momentum. With a historical volatility rate of 59.00%, the RSI 9-day stood at 39.22% on 20 September.
With respect to its five-day moving average, the current Zomedica Corp. price is down by -4.27% percent or -$0.0076. At present, ZOM shares trade -5.60% below its 20-day simple moving average and -15.95% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.90% below its SMA50 and -16.24% below its SMA200.
Stochastic coefficient K was 39.28% and Stochastic coefficient D was 28.70%, while ATR was 0.0074. Given the Stochastic reading of 28.92% for the 14-day period, the RSI (14) reading has been calculated as 39.25%.
Analyst Ratings
Dawson James launched its rating on Zomedica Corp. (AMEX: ZOM) to a Buy in a note to investors on January 06, 2023. Zomedica Corp. (ZOM) has been rated Buy by analysts. According to 0 brokerage firms, ZOM is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Zomedica Corp. stock as buy, with 1 recommending it as overweight.
With a median target price of $0.44, the current consensus forecast for the stock is $0.44 – $0.44. Based on these forecasts, analysts predict Zomedica Corp. (ZOM) will achieve an average price target of $0.44.
